BA
ANIK icon

Boston Advisors’s Anika Therapeutics ANIK Stock Holding History

Boston Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9,290
Closed -$458K – 642
2017
Q2 		$458K Sell
9,290
-170
-2% -$7.83K 0.01% 508
2017
Q1 		$411K Sell
9,460
-735
-7% -$35.1K 0.01% 508
2016
Q4 		$499K Buy
+10,195
New +$471K 0.01% 477
2015
Q4 		– Sell
-91,351
Closed -$2.91M – 656
2015
Q3 		$2.91M Buy
+91,351
New +$3.19M 0.11% 228

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Boston Advisors's ANIK Position: Q3 2017 in Review

Boston Advisors sold out of Anika Therapeutics (ANIK) in Q3 2017, closing a stake of 9,290 shares — an estimated $458K sold.

Boston Advisors first reported a position in ANIK in Q3 2015 and held it in 4 quarters. The position peaked at $2.91M in Q3 2015. 166 funds tracked by Wall St. Rank hold ANIK as of Q3 2017.

  • Boston Advisors reported no remaining Anika Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Boston Advisors sold 9,290 Anika Therapeutics shares in Q3 2017, an estimated $458K.
  • Boston Advisors first reported a position in Anika Therapeutics in Q3 2015 and held it in 4 quarters.
  • Boston Advisors's Anika Therapeutics position peaked at $2.91M in Q3 2015.
  • 166 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2017.

Based on Boston Advisors's 13F filing for Q3 2017, filed 24 Oct 2017.